Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Withdrawn 1Unknown 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 23Squamous Cell Carcinoma of Head and Neck 14Head and Neck Neoplasms 12Lung Neoplasms 10Uterine Cervical Neoplasms 9Neoplasms 9Cholangiocarcinoma 5Carcinoma, Squamous Cell 5Carcinoma 5Mesothelioma, Malignant 4Carcinoma, Hepatocellular 4Tongue Neoplasms 3Small Cell Lung Carcinoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Pancreatic Neoplasms 3Oropharyngeal Neoplasms 3Mouth Neoplasms 3Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Breast Neoplasms 3Biliary Tract Neoplasms 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Ovarian Neoplasms 2Nasopharyngeal Neoplasms 2Mesothelioma 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2

Interventions

Rituximab 5Peripheral Blood Stem Cell Transplantation 4Cyclophosphamide 4ibrutinib 2fludarabine phosphate 2Tacrolimus 2Pentetic Acid 2Methotrexate 2Melphalan 2Lenalidomide 2Etoposide 2Doxorubicin 2Dexamethasone 2Cytarabine 2Carmustine 2umbralisib 1ublituximab 1sargramostim 1romidepsin 1ethanolamine oleate 1antineoplaston AS 2-1 1antineoplaston A10 1Whole-Body Irradiation 1Vincristine 1Trimethoprim, Sulfamethoxazole Drug Combination 1Trimethoprim 1Transplantation 1Thiotepa 1Thalidomide 1Sulfamethoxazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Waldenstrom Macroglobulinemia × Cisplatin × Clear all
NCT00723658 2015-03-06

S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia

SWOG Cancer Research Network

Phase 2 Withdrawn
Lymphoid

Lymphoma, Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡